Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025. Adjusted earnings per share (EPS) of $1.90 beat the Zacks Consensus Estimate ...

Exelixis plans on completing the currently ongoing $500... at 16:35 Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis Gilead ...

The market for Parkinson’s disease (PD) drugs across the seven major geographies (7MM; USA, France, Germany, Italy, UK and Japan) is projected to grow at a compound annual growth rate (CAGR) of 8.9% ...

52.2% of patients met the composite endpoint of the study. Seladelpar can result in clinically meaningful improvements in markers of cholestasis and liver injury in patients with primary biliary ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target remains the same with $95.00. Tyler Van Buren’s ...

In an important regulatory win for Denmark’s Novo Nordisk (NOV: N), the US Food and Drug Administration (FDA) yesterday approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, ...

PITMAN, N.J., Jan. 28, 2025 /PRNewswire/ -- The American Academy of Ambulatory Care Nursing (AAACN) invites nurses, health care organizations, and communities nationwide to celebrate Ambulatory ...

Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.